Treatment and impact of dyslipidemia in diabetic nephropathy

被引：37

作者：

Toyama, Tadashi ^{[1
]}

Shimizu, Miho ^{[1
]}

Furuichi, Kengo ^{[1
]}

Kaneko, Shuichi ^{[2
]}

Wada, Takashi ^{[1
,3
]}

机构：

[1] Kanazawa Univ Hosp, Div Nephrol, Kanazawa, Ishikawa, Japan

[2] Kanazawa Univ, Dept Dis Control & Homeostasis, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan

[3] Kanazawa Univ, Dept Lab Med, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan

来源：

CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2014年 / 18卷 / 02期

关键词：

Diabetic nephropathy; Dyslipidemia; Cardiovascular disease; End-stage renal disease; KIDNEY-DISEASE; LIPID NEPHROTOXICITY; METABOLIC SYNDROME; CLINICAL-PRACTICE; RENAL-DISEASE; RISK; LIPOPROTEINS; CHOLESTEROL; PROGRESSION; OUTCOMES;

D O I：

10.1007/s10157-013-0898-1

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Recent epidemiological research revealed that dyslipidemia is a risk factor for development and progression of diabetic nephropathy. Results from interventional studies revealed the possibility that anti-hyperlipidemic agents have a better effect on diabetic nephropathy through improvement of albuminuria and loss of renal function. In addition, dyslipidemia may be a consequence of albuminuria and renal dysfunction, thereby perpetuating kidney damage. Today, the proportion of diabetic patients receiving statins is increasing due to their beneficial effect on cardiovascular mortality. However, treatment for patients should be determined based on consideration of the risk and benefit of the treatment. More insight into the pathogenesis of diabetic nephropathy and the effects of life-style changes is required.

引用

页码：201 / 205

页数：5

共 45 条

[1] The safety of rosuvastatin as used in common clinical practice - A postmarketing analysis [J].

Alsheikh-Ali, AA ;

Ambrose, MS ;

Kuvin, JT ;

Karas, RH .

CIRCULATION, 2005, 111 (23) :3051-3057

[2] Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) [J].

Ansquer, JC ;

Foucher, C ;

Rattier, S ;

Taskinen, MR ;

Steiner, G .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) :485-493

[3] The compositional abnormalities of lipoproteins in diabetic renal failure [J].

Attman, PO ;

Knight-Gibson, C ;

Tavella, M ;

Samuelsson, O ;

Alaupovic, P .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (11) :2833-2841

[4] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].

Baigent, Colin ;

Landray, Martin J. ;

Reith, Christina ;

Emberson, Jonathan ;

Wheeler, David C. ;

Tomson, Charles ;

Wanner, Christoph ;

Krane, Vera ;

Cass, Alan ;

Craig, Jonathan ;

Neal, Bruce ;

Jiang, Lixin ;

Hooi, Lai Seong ;

Levin, Adeera ;

Agodoa, Lawrence ;

Gaziano, Mike ;

Kasiske, Bertram ;

Walker, Robert ;

Massy, Ziad A. ;

Feldt-Rasmussen, Bo ;

Krairittichai, Udom ;

Ophascharoensuk, Vuddidhej ;

Fellstrom, Bengt ;

Holdaas, Hallvard ;

Tesar, Vladimir ;

Wiecek, Andrzej ;

Grobbee, Diederick ;

de Zeeuw, Dick ;

Gronhagen-Riska, Carola ;

Dasgupta, Tanaji ;

Lewis, David ;

Herrington, William ;

Mafham, Marion ;

Majoni, William ;

Wallendszus, Karl ;

Grimm, Richard ;

Pedersen, Terje ;

Tobert, Jonathan ;

Armitage, Jane ;

Baxter, Alex ;

Bray, Christopher ;

Chen, Yiping ;

Chen, Zhengming ;

Hill, Michael ;

Knott, Carol ;

Parish, Sarah ;

Simpson, David ;

Sleight, Peter ;

Young, Alan ;

Collins, Rory .

LANCET, 2011, 377 (9784) :2181-2192

[5] Risk for myopathy with statin therapy in high-risk patients [J].

Ballantyne, CM ;

Corsini, A ;

Davidson, MH ;

Holdaas, H ;

Jacobson, TA ;

Leitersdorf, E ;

März, W ;

Reckless, JPD ;

Stein, EA .

ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :553-564

[6] Risk of incident diabetes among patients treated with statins: population based study [J].

Carter, Aleesa A. ;

Gomes, Tara ;

Camacho, Ximena ;

Juurlink, David N. ;

Shah, Baiju R. ;

Mamdani, Muhammad M. .

BMJ-BRITISH MEDICAL JOURNAL, 2013, 346

[7] Native and oxidized low-density lipoproteins enhance superoxide production from diabetic rat glomeruli [J].

Chen, HC ;

Tan, MS ;

Guh, JY ;

Tsai, JH ;

Lai, YH .

KIDNEY & BLOOD PRESSURE RESEARCH, 2000, 23 (02) :133-137

[8] Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS) [J].

Colhoun, Helen M. ;

Betteridge, D. John ;

Durrington, Paul N. ;

Hitman, Graham A. ;

Neil, H. Andrew W. ;

Livingstone, Shona J. ;

Charlton-Menys, Valentine ;

DeMicco, David A. ;

Fuller, John H. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (05) :810-819

[9] Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study [J].

Davis, T. M. E. ;

Ting, R. ;

Best, J. D. ;

Donoghoe, M. W. ;

Drury, P. L. ;

Sullivan, D. R. ;

Jenkins, A. J. ;

O'Connell, R. L. ;

Whiting, M. J. ;

Glasziou, P. P. ;

Simes, R. J. ;

Kesaniemi, Y. A. ;

Gebski, V. J. ;

Scott, R. S. ;

Keech, A. C. .

DIABETOLOGIA, 2011, 54 (02) :280-290

[10] Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis [J].

Fox, Caroline S. ;

Matsushita, Kunihiro ;

Woodward, Mark ;

Bilo, Henk J. G. ;

Chalmers, John ;

Lambers Heerspink, Hiddo J. ;

Lee, Brian J. ;

Perkins, Robert M. ;

Rossing, Peter ;

Sairenchi, Toshimi ;

Tonelli, Marcello ;

Vassalotti, Joseph A. ;

Yamagishi, Kazumasa ;

Coresh, Josef ;

de Jong, Paul E. ;

Wen, Chi-Pang ;

Nelson, Robert G. .

LANCET, 2012, 380 (9854) :1662-1673

← 1 2 3 4 5 →